Study Stopped
Biobank - no investigation involved
Personalize My Treatment (PMT) Registry
PMT
A Large-scale Longitudinal Oncology Registry
1 other identifier
observational
10,000
1 country
14
Brief Summary
The 'Personalize My treatment' (PMT) platform is a novel form of biobanking in which cancer patients willingly consent to provide residual, clinical samples (surplus after diagnostic testing) of their tumors for cancer research, to give access to their medical record for data collection and then followed prospectively throughout the trajectory of their illness. They further willingly consent to be recontacted for being informed of other research projects, including clinical trials.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
14 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 30, 2015
CompletedFirst Posted
Study publicly available on registry
February 4, 2015
CompletedStudy Start
First participant enrolled
November 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 13, 2024
CompletedFebruary 4, 2025
February 1, 2025
9.1 years
January 30, 2015
February 3, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
The primary objective of PMT is to create a collection of cancer patient biospecimens and annotated data that will be used for clinical trial matching and to advance cancer research.
Longitudinal
Eligibility Criteria
Cancer patients with all solid tumor types.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Study Sites (14)
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
Centre Hospitalier Universitaire Dr-Georges-L.-Dumont
Moncton, New Brunswick, E1C 2Z3, Canada
The Moncton Hospital
Moncton, New Brunswick, E1C 6Z8, Canada
QE II Health Sciences Centre
Halifax, Nova Scotia, B3H 1V8, Canada
London Health Science Centre
London, Ontario, Canada
The Ottawa Hospital
Ottawa, Ontario, K1H 8L6, Canada
Odette Cancer Centre - Sunnybrook Hospital
Toronto, Ontario, M4N 3M5, Canada
Centre hospitalier de l'Université de Montréal
Montreal, Quebec, H2X 0A9, Canada
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
MUHC McGill University Health Center
Montreal, Quebec, H4A 3J1, Canada
Centre hospitalier universitaire de Québec - Université Laval
Québec, Quebec, H3T 1Y6, Canada
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, J1G 2E8, Canada
CIUSSS de la Mauricie-et-du-Centre-du-Québec - Centre Hospital Régional
Trois-Rivières, Quebec, G8Z 3R9, Canada
Related Links
Biospecimen
Tissue (from surgical resection or biopsy) and blood
MeSH Terms
Conditions
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 30, 2015
First Posted
February 4, 2015
Study Start
November 1, 2015
Primary Completion
December 13, 2024
Last Updated
February 4, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will share
The BDAC (Biospecimen and Data Access Committee) authorizes access requests from researchers to the PMT Platform's biospecimens and data. It meets as needed to review requests in accordance with the PMT Biospecimen and Data Access Policy. Requests will be evaluated based on scientific merit, availability of sample and alignment with the mission of the PMT Platform and Exactis. BDAC is responsible for verifying that the proposed project has received appropriate ethics approval and proof of such approval has been provided.